PIK3CA by NGS: Advanced Genetic Cancer Testing
Comprehensive Introduction to PIK3CA Genetic Testing
The PIK3CA by NGS test represents a breakthrough in precision oncology, utilizing Next Generation Sequencing technology to analyze the PIK3CA gene for cancer-related mutations. This sophisticated genetic analysis provides critical information that directly impacts cancer treatment decisions and patient outcomes. The PIK3CA gene encodes the p110α catalytic subunit of PI3K, a key enzyme in the PI3K/AKT/mTOR signaling pathway that regulates cell growth, proliferation, and survival.
Mutations in the PIK3CA gene are among the most common genetic alterations found in human cancers, occurring in approximately 30-40% of hormone receptor-positive breast cancers, 25-30% of head and neck squamous cell carcinomas, and significant percentages of colorectal, endometrial, and ovarian cancers. The identification of these mutations through NGS testing enables oncologists to implement targeted therapeutic strategies that can significantly improve treatment efficacy and patient survival rates.
What the PIK3CA by NGS Test Detects
This advanced genetic test specifically identifies and characterizes mutations within the PIK3CA gene using high-throughput Next Generation Sequencing technology. The test detects:
- Hotspot mutations in exons 9 and 20 of the PIK3CA gene
- Common activating mutations including E542K, E545K, and H1047R
- Rare and novel PIK3CA mutations that may impact treatment response
- Mutation frequency and variant allele fraction for quantitative assessment
- Co-existing genetic alterations that may influence therapeutic decisions
Who Should Consider PIK3CA Testing
This genetic test is particularly valuable for patients experiencing or diagnosed with:
Cancer Patients and Suspected Cases
- Patients with newly diagnosed breast cancer, especially hormone receptor-positive types
- Individuals with advanced or metastatic solid tumors
- Patients with colorectal cancer considering targeted therapy options
- Those with head and neck squamous cell carcinoma
- Patients with endometrial or ovarian cancers
- Individuals with treatment-resistant cancers seeking alternative therapeutic options
Symptoms and Clinical Indications
- Unexplained weight loss and fatigue in cancer patients
- Progressive disease despite standard treatment regimens
- Family history of cancer with potential genetic predisposition
- Need for personalized treatment planning in advanced cancers
- Evaluation for clinical trial eligibility requiring specific mutation status
Significant Benefits of PIK3CA Genetic Testing
Undergoing PIK3CA by NGS testing offers numerous advantages for cancer management:
- Personalized Treatment Selection: Identifies patients who may benefit from PI3K inhibitors and other targeted therapies
- Improved Treatment Outcomes: Enables selection of therapies with higher likelihood of success based on genetic profile
- Reduced Treatment Toxicity: Helps avoid ineffective treatments and their associated side effects
- Prognostic Information: Provides insights into disease behavior and potential treatment resistance
- Clinical Trial Matching: Facilitates enrollment in targeted therapy clinical trials
- Comprehensive Genetic Profile: Offers broader mutation analysis beyond single-gene testing
Understanding Your PIK3CA Test Results
Interpreting your genetic test results requires professional medical guidance, but here’s a general overview:
Positive Results
A positive result indicates the presence of PIK3CA mutations. This finding may qualify you for targeted therapies such as PI3K inhibitors, which specifically target the mutated pathway. Your oncologist will discuss appropriate treatment options based on the specific mutation detected and your overall clinical picture.
Negative Results
A negative result means no PIK3CA mutations were detected in the sample analyzed. This information helps guide treatment away from PI3K-targeted therapies and toward other effective options. However, it’s important to note that other genetic alterations may still be driving cancer growth.
Variant of Uncertain Significance
In some cases, the test may identify genetic changes whose clinical significance is not yet fully understood. These variants require careful interpretation by genetic specialists and may warrant additional testing or monitoring.
Test Details and Pricing
| Test Parameter | Details |
|---|---|
| Test Name | PIK3CA by NGS |
| Discount Price | $500 USD |
| Regular Price | $1000 USD |
| Turnaround Time | 10-15 days |
| Sample Type | Peripheral blood (10ml) |
| Test Components | Please request collection material |
| Pre-test Instructions | PIK3CA by NGS can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad. |
Nationwide Testing Availability
We have branches across the United States, making advanced genetic testing accessible to patients nationwide. Our state-of-the-art facilities in major cities including New York, Los Angeles, Chicago, Houston, Phoenix, and Philadelphia ensure that you receive the highest quality genetic analysis with rapid turnaround times.
Take Control of Your Cancer Treatment Journey
Don’t leave your treatment decisions to chance. The PIK3CA by NGS test provides the genetic intelligence needed to make informed decisions about your cancer care. With our discounted price of only $500 USD, this advanced testing is more accessible than ever.
Ready to take the next step in your cancer care? Call us today at +1(267) 388-9828 to schedule your PIK3CA by NGS test or to speak with our genetic counseling team. Our specialists are available to answer your questions and guide you through the testing process.
Book your test now and gain the genetic insights that could transform your cancer treatment approach. Early genetic testing can make a significant difference in treatment outcomes and quality of life.
